Therapy of bronchial asthma with adenosine receptor agonists or antagonists.

Abstract

Adenosine is an endogenous nucleoside that is released under pathological conditions and interacts with four G-protein-coupled receptor subtypes. These receptors are widely distributed throughout the body. They are involved in many central and peripheral processes, including immunological and inflammatory responses. In inflammatory and asthmatic conditions, the extracellular concentration of adenosine increases in the airway tissue. It enhances mast cell degranulation and bronchoconstriction, but may also inhibit eosinophil or lymphocyte function or modulate reactive oxygen species generation in neutrophils. Despite a large number of studies clearly indicating the effects of adenosine in vitro, many aspects of the mechanisms involved in the adenosine-mediated responses are still unclear, and our knowledge is limited in understanding the complex multifactorial interactions occurring in the whole body. The discovery of adenosine receptor compounds acting with increasing selectivity will bring new approaches to the use of adenosine receptor agonists and antagonists and may clarify some of the current uncertainties. On the basis of our present knowledge, the development of adenosine A(2A)- or (A3)-receptor agonists as antiinflammatory agents or A(2B)-receptor antagonists as inhibitors of mast cell degranulation for the treatment of asthma holds promise.

• Authors: D Marx, C I Ezeamuzie, K Nieber, I Szelenyi
• Journal: Drug news & perspectives (Drug News Perspect) Vol. 14 Issue 2 Pg. 89-100 (Mar 2001) ISSN: 0214-0934 [Print] United States
• PMID: 12819800 (Publication Type: Journal Article)
• Copyright: (c) 2001 Prous Science. All rights reserved.